Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
Quick facts
Phase 3 pipeline
- Lenacapavir Injection · Infectious Disease
Lenacapavir is a first-in-class HIV capsid inhibitor that prevents the uncoating of HIV viral particles, blocking early steps of viral replication.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida portfolio CI brief
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida pipeline updates RSS
Frequently asked questions about Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
What is Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida's pipeline?
Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Lenacapavir Injection.
Related
- Sector hub: All tracked pharma companies